MARKET

EPIX

EPIX

ESSA Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.94
-0.71
-2.66%
Opening 15:03 02/25 EST
OPEN
26.47
PREV CLOSE
26.65
HIGH
26.70
LOW
25.23
VOLUME
117.00K
TURNOVER
--
52 WEEK HIGH
32.69
52 WEEK LOW
3.000
MARKET CAP
997.04M
P/E (TTM)
-25.4763
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
ESSA Pharma Reports Collaboration With Astellas To Evaluate Combo Of EPI-7386, Enzalutamide For Patients With Metastatic Castration-Resistant Prostate Cancer
ESSA Pharma Inc. (NASDAQ:EPIX) ("ESSA" or the "Company"), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that
Benzinga · 7h ago
BRIEF-Essa Pharma Announces Clinical Collaboration With Astellas
reuters.com · 7h ago
ESSA Pharma Announces Clinical Collaboration with Astellas to Evaluate the Combination of EPI-7386 and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer
HOUSTON, Texas and VANCOUVER, Canada, Feb. 25, 2021 /CNW/ - ESSA Pharma Inc.
CNW Group · 8h ago
--Analyst Actions: HC Wainwright Adjusts ESSA Pharma PT to $32 From $36, Maintains Buy Rating
MT Newswires · 8h ago
ESSA Pharma Announces Closing of $130 Million Public Offering of Common Stock
VANCOUVER, BC and , /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (Nasdaq: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced the closing of an underwritt...
PR Newswire - PRF · 3d ago
ESSA Pharma Raises $130 Million In Gross Proceeds From Common Stock Offering
MT Newswires · 3d ago
Essa Pharma Prices Upsized Public Offering of Common Shares at $27 Per Share
MT Newswires · 02/18 07:15
ESSA Pharma prices equity offering at $27
ESSA Pharma (EPIX) has priced its public offering of ~4.8M common shares at $27.00/share, for gross proceeds of ~$130.4M.Underwriters' over-allotment is an additional ~724.6K shares.Net proceeds will be used for
Seekingalpha · 02/18 04:31
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EPIX. Analyze the recent business situations of ESSA Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EPIX stock price target is 38.80 with a high estimate of 42.00 and a low estimate of 36.00.
EPS
Institutional Holdings
Institutions: 48
Institutional Holdings: 26.66M
% Owned: 69.36%
Shares Outstanding: 38.44M
TypeInstitutionsShares
Increased
15
3.19M
New
9
830.93K
Decreased
9
1.23M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.76%
Pharmaceuticals & Medical Research
-1.03%
Key Executives
Non-Executive Chairman/Independent Director
Richard Glickman
President/Chief Executive Officer/Director
David Parkinson
Chief Financial Officer/Primary Contact
David Wood
Chief Operating Officer/Executive Vice President
Peter Virsik
Other
Alessandra Cesano
Director
Ari Brettman
Director
Alex Martin
Director
Scott Requadt
Director
Marella Thorell
Independent Director
Franklin Berger
Independent Director
Gary Sollis
Independent Director
Sanford Zweifach
  • Dividends
  • Splits
  • Insider Activity
No Data
About EPIX
ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

Webull offers kinds of ESSA Pharma Inc stock information, including NASDAQ:EPIX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EPIX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EPIX stock methods without spending real money on the virtual paper trading platform.